


## PHARMACEUTICAL 2020

## RIGEL PHARMACEUTICALS INC Rank 179 of 362







## PHARMACEUTICAL 2020

## RIGEL PHARMACEUTICALS INC Rank 179 of 362



The relative strengths and weaknesses of RIGEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RIGEL PHARMACEUTICALS INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 112% points. The greatest weakness of RIGEL PHARMACEUTICALS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -173%, being 130% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	119,005
Cost of Goods Sold	906
Intangible Assets	0
Liabilities, Current	58,212
Liabilities, Non-Current	0
Other Assets	26,405
Other Compr. Net Income	2,244
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	2,159
Research and Development	52,885
Revenues	59,288
Selling, General and Administrative Expense	74,588

Output Variable	Value in 1000 USD
Assets	147,569
Liabilities	58,212
Expenses	128,379
Stockholders Equity	89,357
Net Income	-69,091
Comprehensive Net Income	-67,969
Economic Capital Ratio	-173%